Bristol-Myers Squibb announced plans to lay off 4,300 employees and close more than half of its manufacturing plants in a cost-saving, "right-sizing" move. Followed by Pfizer and Merck, it's the third big pharma company to take action against the looming generics competition. In the Pipeline's Derek Lowe thinks it's not a bad thing, as long as R&D is left alone to do what they do best -- discover new drug compounds.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.